ICON plc (NASDAQ:ICLR) is expected to report second quarter earnings results, after market close, on Wednesday 22nd July 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 1.10 per share from revenue of $ 598.77 million.
Looking ahead, the full year income are expected at $ 5.95 per share on the revenues of $ 2694.62 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,972.00 million ~ $ 3,092.00 million, where as bottomline are predicted in a range of $ 7.55 ~ $ 7.85 per share
Click Here For More Historical Outlooks Of ICON plc
Previous Quarter Performance
ICON plc unwinded income for the first quarter of $ 1.70 per share, from the revenue of $ 715.10 million. The quarterly earnings expanded 4.29 percent while revenues grew 7.02 percent compared with the same quarter last year.
The consensus estimates are income of $ 1.68 per share from $ 707.22 million in revenue. The bottom line results beat street analysts by $ 0.02 or 1.19 percent, at the same time, top line results outshined analysts by $ 7.88 million or 1.11 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of ICON plc
Stock Performance
According to the previous trading day, closing price of ICLR was $ 190.05, representing a 82.25 % increase from the 52 week low of $ 104.28 and a 2.12 % decrease over the 52 week high of $ 194.17.
The company has a market capital of $ 9.98 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ICLR” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The companys clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services.
